Hims will sell generic Semaglutide in 2026

Clearly, there's no love lost between Hims and Novo Nordisk. The two companies parted ways quite publicly (with drama that is somewhat rare for public companies) just recently:

After two months, Novo Nordisk and HIMS part ways

Novo Nordisk and HIMS end their partnership that brought cheaper Wegovy (Semaglutide) to customers of HIMS.

GLP1 GuideGLP1.Guide Staff

You'd think that would be the end of Hims and Semaglutide (well, at least officially procured Semaglutide), but it looks like the recent Novo Nordisk failure to protect their patent protections is going to play a part:

Novo Nordisk patent protections lapse in Canada

Novo Nordisk’s patent protections lapse early after forgetting to pay a small fee allows a Canadian Generic to get to market faster.

GLP1 GuideGLP1.Guide Staff

It turns out Hims has started selling generic Semaglutide in Canada:

Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.

CNBCBrandon Gomez

We'll get into what HIMS had to say, their price, and what Canadian export agreements could mean for GLP1s being widely accessible below.

The rest of this article is no longer available for free – if you'd like to read the rest of our analysis, check us out on Substack: